ArticleJournal of clinical immunology2022

Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency.

Manuel Santamaria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.